Engin Gul (E Gul)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Multiple Myeloma

Prognostic Factors

Monoclonal Antibody

Acute Lymphoblastic Leukemia

Top Venues

Nature medicine

Blood cancer journal

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine 30 (2) (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine 30 (2) (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine 30 (2) (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine 30 (2) (2024)
Arleigh McCurdy, Alissa Visram, Martha L Louzada, Darrell White, Stephen Parkin, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Suzanne Trudel
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial. Blood cancer journal 14 (1) (2024)
Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Alissa Visram
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nature medicine (2024)
Julie Côté, Richard LeBlanc, Hira S Mian, Michael P Chu, Arleigh McCurdy, Esther Masih-Khan, Jiandong Su, Victor H Jimenez-Zepeda, Kevin Song, Martha Louzada, Darrell White, Michael Sebag, Anthony Reiman, Julie Stakiw, Rami Kotb, Debra Bergstrom, Muhammad Aslam, Rayan Kaedbey, Christopher P Venner, Engin Gul, Donna Reece
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood cancer journal 13 (1) (2023)
Alissa Visram, A De La Torre, D White, J Su, E Masih-Khan, M Chu, V Jimenez-Zepeda, Arleigh McCurdy, R LeBlanc, K Song, Hira S Mian, M Louzada, M Sebag, D Bergstrom, J Stakiw, A Reiman, R Kotb, M Aslam, C Venner, R Kaedbey, Engin Gul, D Reece
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood cancer journal 13 (1) (2023)
Richard LeBlanc, Hira S Mian, Donna Reece, Jiandong Su, Esther Masih-Khan, Michael Chu, Victor H Jimenez-Zepeda, Michael Sebag, Kevin Song, Martha Louzada, Rami Kotb, Alissa Visram, Darrell White, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rayan Kaedbey, Engin Gul, Christopher P Venner
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis. European journal of haematology (2023)